EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)

Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial

Akhil Santhosh iD, Atul Sharma iD, Sameer Bakhshi iD, Akash Kumar iD, Vinod Sharma iD, Prabhat Singh Malik iD, Raja Pramanik iD, Ajay Gogia iD, Chandra Prakash Prasad iD, Tushar Sehgal iD, Sneha Gund, Arundhathi Dev und 6 weitere

Journal of Clinical Oncology · 20.05.2024 · 42 (15) · 1821-1829

DOI: 10.1200/jco.23.01730 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.05.2024. Verfasst von Akhil Santhosh und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, BRAIRCH, AIIMS, Delhi, India. Hauptthemen laut MEDLINE: Capecitabine, Hand-Foot Syndrome, Diclofenac, Antimetabolites, Antineoplastic. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Hand-foot syndrome (HFS) is a dose-limiting side effect of capecitabine. Celecoxib prevents HFS by inhibiting cyclooxygenase-2 (COX-2) that is upregulated because of the underlying associated inflammation. However, systemic side effects of celecoxib have limited routine prescription. Topical diclofenac inhibits COX-2 locally with minimal risk of systemic adverse events. Therefore, we conducted this study to assess the efficacy of topical diclofenac in the prevention of capecitabine-induced HFS. METHODS In this single-site phase III randomized double-blind trial, we enrolled patients with breast or GI cancer who were planned to receive capecitabine-based treatment. Participants were randomly assigned in a 1:1 ratio to receive topical diclofenac or placebo gel for 12 weeks or until the development of HFS, whichever occurred earlier. The primary end point was the incidence of grade 2 or 3 HFS (Common Terminology Criteria for Adverse Events version 5), which was compared between the two groups using simple logistic regression. RESULTS In total, 264 patients were randomly assigned to receive topical diclofenac gel (n = 131) or placebo (n = 133). Grade 2 or 3 HFS was observed in 3.8% of participants in the diclofenac group compared with 15.0% in the placebo group (absolute difference, 11.2%; 95% CI, 4.3 to 18.1; P = .003). Grade 1-3 HFS was lower in the diclofenac group than in the placebo group (6.1% v 18.1%; absolute risk difference, 11.9%; 95% CI, 4.1 to 19.6). Capecitabine dose reductions because of HFS were less frequent in the diclofenac group (3.8%) than in the placebo group (13.5%; absolute risk difference, 9.7%; 95% CI, 3.0 to 16.4). CONCLUSION Topical diclofenac prevented HFS in patients receiving capecitabine. This trial supports the use of topical diclofenac to prevent capecitabine-associated HFS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CapecitabineHand-Foot SyndromeDiclofenacAntimetabolites, AntineoplasticHumansDouble-Blind MethodFemaleMaleMiddle AgedAgedBreast NeoplasmsAdministration, TopicalAdultGastrointestinal NeoplasmsAnti-Inflammatory Agents, Non-Steroidal

Substanzen

CapecitabineDiclofenacAntimetabolites, AntineoplasticAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Department of Medical Oncology, BRAIRCH, AIIMS, Delhi, India.
  • Department of Medical Oncology, National Cancer Institute Jhajjar, AIIMS, New Delhi, India.
  • Department of Medical Oncology (LAB), BRAIRCH, AIIMS, Delhi, India.
  • Department of Laboratory Medicine, AIIMS, Delhi, India.
  • Department of Medical Oncology, Tom Baker Cancer Centre Calgary, Calgary, Canada.
  • Department of Biostatistics, AIIMS, Delhi, India.

ORCID-Profile: Akhil Santhosh, Atul Sharma, Sameer Bakhshi, Akash Kumar, Vinod Sharma, Prabhat Singh Malik, Raja Pramanik, Ajay Gogia, Chandra Prakash Prasad, Tushar Sehgal, Winson Y Cheung, Saran Kumar, Atul Batra

Zitieren

APA

Santhosh, A., Sharma, A., Bakhshi, S., Kumar, A., Sharma, V., Malik, P. S., Pramanik, R., Gogia, A., Prasad, C. P., Sehgal, T., Gund, S., Dev, A., Cheung, W. Y., Pandey, R. M., Kumar, S., Gupta, I., Batra, A., & D-TORCH Trial Investigators (2024). Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial. Journal of Clinical Oncology, 42(15), 1821-1829. https://doi.org/10.1200/jco.23.01730

Vancouver

Santhosh A, Sharma A, Bakhshi S, Kumar A, Sharma V, Malik PS, et al. Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial. Journal of Clinical Oncology. 2024;42(15):1821-1829. doi:10.1200/jco.23.01730

BibTeX
@article{Santhosh2024,
  author = {Santhosh, Akhil and Sharma, Atul and Bakhshi, Sameer and Kumar, Akash and Sharma, Vinod and Malik, Prabhat Singh and Pramanik, Raja and Gogia, Ajay and Prasad, Chandra Prakash and Sehgal, Tushar and Gund, Sneha and Dev, Arundhathi and Cheung, Winson Y and Pandey, R M and Kumar, Saran and Gupta, Ishaan and Batra, Atul and D-TORCH Trial Investigators, D-TORCH Trial Investigators},
  title = {Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {15},
  pages = {1821--1829},
  doi = {10.1200/jco.23.01730}
}
Kostenlos starten →